戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 .3 and ZC410.7 manifest larval arrest in the second generation.
2 -ureido)-pentanedioic acid ((18)F-DCFPyL), a second-generation (18)F-labeled PSMA ligand.
3 amino]-pentyl)-ureido)-pentanedioic acid], a second-generation (18)F-PSMA-ligand) in patients with PC
4                                         STOP second generation (2G)-tyrosine kinase inhibitor (TKI) i
5   The purpose of this study was to develop a second-generation (99m)Tc-labeled PSMA-targeted tracer i
6                                              Second-generation ABL1 kinase inhibitors induce more pot
7 unctional theory calculations, combined with second-generation absolutely localized molecular orbital
8  an optimization process that has produced a second-generation acridone series with significant impro
9 ion aphids had cross-generational impacts on second-generation adults, and the impact on fecundity wa
10                                          The second-generation agent, dolutegravir (DTG), has enjoyed
11 ion in advSM, and the efficacy and safety of second-generation agents, such as the switch-control inh
12 role of ensartinib in patients in whom other second-generation ALK inhibitors have been unsuccessful
13 stant to currently available TKIs, including second-generation ALK TKIs, and is being investigated in
14                         Here, we show that a second-generation amino-acyl tRNA synthetase (aaRS)/tRNA
15 ent the design, synthesis, and evaluation of second-generation analogues, which led to the discovery
16 ynthesis, and pharmacological evaluation of "second generation" analogues of 1 whereby subtle modific
17                              Enzalutamide, a second-generation androgen receptor (AR) antagonist, has
18           Enzalutamide (MDV3100) is a potent second-generation androgen receptor antagonist approved
19 elationship also persisted in experiments on second-generation animals, and larval lipid consumption
20  Inhibition of the androgen receptor (AR) by second-generation anti-androgens is a standard treatment
21 d safety of idelalisib in combination with a second-generation anti-CD20 antibody, ofatumumab, in a s
22                              Olanzapine is a second-generation anti-psychotic drug used to prevent ne
23 K activation as a mechanism of resistance to second-generation antiandrogen therapy, highlighting the
24 r NRG1 activity have an inferior response to second-generation antiandrogen therapy.
25                  Enzalutamide (MDV3100) is a second-generation antiandrogenic drug that was approved
26                   Despite the development of second-generation antiandrogens, acquired resistance to
27 er recommend initial treatment with either a second-generation antidepressant (SGA) or cognitive beha
28 ly significant difference in the efficacy of second-generation antidepressants (SGAs) versus most oth
29 , double-blind, placebo-controlled trials of second-generation antidepressants adjunctive to a mood s
30                                              Second-generation antidepressants are the first-line opt
31 tween either cognitive behavioral therapy or second-generation antidepressants to treat patients with
32                                              Second-generation antidepressants were associated with a
33                   For the most commonly used second-generation antidepressants, the lower range of th
34                                            A second generation antigene peptide oligonucleotide targe
35                              The efficacy of second-generation antihistamines was evaluated on the da
36               The second included studies on second-generation antipsychotic combination therapies (S
37                                              Second-generation antipsychotic drugs (SGAs) are essenti
38 acebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (o
39 ering 12 weeks of prospective treatment with second-generation antipsychotic drugs.
40                               In particular, second generation antipsychotics, like first generation
41 ed hazard ratio, 3.06; 95% CI, 1.32-7.05) or second-generation antipsychotics (adjusted hazard ratio,
42 es not support routine use of haloperidol or second-generation antipsychotics for prevention of delir
43 ipolar disorder over the past 20 years, with second-generation antipsychotics in large measure suppla
44               There is limited evidence that second-generation antipsychotics may lower delirium inci
45               There is limited evidence that second-generation antipsychotics may lower the incidence
46 creased over the past 20 years, with several second-generation antipsychotics receiving regulatory ap
47 es not support routine use of haloperidol or second-generation antipsychotics to treat delirium in ad
48 e SOE), or mortality between haloperidol and second-generation antipsychotics versus placebo.
49                                      Several second-generation antipsychotics were superior to halope
50 andomised controlled trials (RCTs) comparing second-generation antipsychotics with placebo.
51 s in the use of mood stabilizers, first- and second-generation antipsychotics, and antidepressants am
52          For direct comparisons of different second-generation antipsychotics, there was no differenc
53 functioning (low SOE) for haloperidol versus second-generation antipsychotics, with insufficient or n
54 rther increased by both first-generation and second-generation antipsychotics.
55 enia, but we found little difference between second-generation antipsychotics.
56  scanned at baseline prior to treatment with second-generation antipsychotics.
57                                     Although second-generation antiseizure medications have not subst
58                               Since 1989, 18 second-generation antiseizure medications have reached t
59                                         Some second-generation antiseizure medications have shown adv
60 els following treatment with volanesorsen, a second-generation antisense drug targeting apoC-III, wer
61                               Custirsen is a second-generation antisense oligonucleotide that inhibit
62                         Among the first- and second-generation APDs that we tested, clozapine exhibit
63 ive to circumvent this issue, we developed a second-generation approach for the synthesis of PODs by
64                  Additionally, we prepared a second-generation barcoded SIVmac239 stock (SIVmac239M2)
65 n this study, we report the development of a second-generation BET protein degrader, BETd-246, which
66 than one year after the introduction of this second generation beta-lactam antibiotic into clinical p
67                                              Second-generation beta-lactamase inhibitors containing a
68                  One of the drawbacks during second-generation biofuel production from plant lignocel
69 , which are valuable characteristics for the second-generation biofuels industry.
70 ss (Panicum virgatum), a strategic plant for second-generation biofuels.
71 scular leak induction yields a fully active, second-generation biologic, s-DAB-IL-2(V6A), which elici
72    The performance of the microneedle array, second generation biosensor for lactate detection was as
73 persisted upon propagation of aggregation to second-generation biosensor cells.
74 rate the capability of microneedle arrays as second generation biosensors we have functionalized gold
75 e C terminus of CA are potently inhibited by second-generation BVM analogs.
76            We recently reported a series of "second-generation" BVM analogs that display markedly imp
77                                         This second-generation cancer co-therapeutic protein is optim
78 elihood of reversion and enhance safety in a second-generation Candid#1 vaccine.
79 elihood of reversion and enhance safety in a second-generation Candid#1 vaccine.IMPORTANCE The live-a
80 and P removal coupled to N2O generation in a second generation CANDO process, CANDO+P.
81 ) light chain kappa or lambda, we designed a second-generation CAR targeting Igkappa, IGK CAR.
82 TRuC-T cells kill tumor cells as potently as second-generation CAR-T cells, but at significant lower
83 lls to that in T cells transduced to express second-generation CARs and found that cell expansion enh
84                   These results suggest that second-generation CARs can activate additional sources o
85  vivo antitumor efficacy, we found that only second-generation CARs induced the expression of a const
86 ral constraints imparted by the structure of second-generation CARs(2).
87 ss-linked via olefin metathesis using Grubbs second generation catalyst.
88  (DFT), the reactivity of the Hoveyda-Grubbs second-generation catalyst 2 with allylbenzene, and disc
89  bis(allyoxy)methyl derivatives using Grubbs second-generation catalyst followed by olefin isomerizat
90 , using only 2.5 mol % of the Hoveyda-Grubbs second-generation catalyst in both metathesis and transf
91 nt in dichloromethane using a Hoveyda-Grubbs second-generation catalyst.
92                                   ABL001 and second-generation catalytic inhibitors have similar cell
93 l report clinical trial results evaluating a second-generation CD19-directed chimeric antigen recepto
94                                            A second-generation CDI, APT-6K, exerted bactericidal acti
95  of the CD3epsilon cytoplasmic domain into a second-generation chimeric antigen receptor (CAR) improv
96 ion or pharmacologic blockade with the novel second-generation CHK1 inhibitor prexasertib (LY2606368)
97  In this study, we report the development of second-generation cobalt- and maleimide-based liposomes
98                                            A second-generation cocktail, MBP134(AF), engineered to ef
99 ern settings, asthma is more prevalent among second-generation compared to first-generation migrants.
100           To understand more about how these second-generation compounds block HIV-1 maturation, here
101           The expanded chemical scaffolds of second-generation compounds mediate interactions with th
102                                    Recently, second-generation CRISPR/Cas9 activation systems based o
103       The photogenerated intermediate of the second-generation DASA was photo-accumulated at low temp
104                                    First and second-generation DASAs share a common photoisomerizatio
105 nogashira coupling into a methoxy-terminated second generation dendrimer with persistent globular sha
106 zed, is critical to the development of their second-generation derivatives to improve drug potency to
107 significantly lower in patients treated with second-generation DES (odds ratio, 0.51; 95% confidence
108                           Patients receiving second-generation DES for the treatment SVG disease have
109   We aimed to compare efficacy and safety of second-generation DES over BMS in large coronary culprit
110 P<0.001) were lower in patients treated with second-generation DES, but not with first-generation DES
111 eived first-generation DES, and 47% received second-generation DES.
112                                          The second-generation design relies on the use of the Henry
113                                Moreover, the second-generation design was also associated with strong
114 s relative to input H2O2 concentrations, the second-generation dihydroxy hydroperoxy peroxy radical (
115 ric protein with reduced vascular leak, is a second-generation diphtheria-toxin-based fusion protein
116 based therapies including paclitaxel and the second-generation docetaxel are currently limited by sev
117 al structure of PDE5 complexed with the sole second generation drug avanafil.
118 eriority of thin-strut biodegradable polymer second-generation drug-eluting stent to the first-genera
119 ere is a paucity of contemporary data on the second-generation drug-eluting stent use within SVG, and
120 -metal stents (BMS) and first-generation and second-generation drug-eluting stents (DES1 and DES2, re
121 st-generation drug-eluting stents (DES1) and second-generation drug-eluting stents (DES2).
122 eds to be assessed individually, but overall second-generation drugs are less likely to cause pharmac
123 mography myocardial perfusion imaging with a second-generation dual-source scanner.
124 ion, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials h
125                                     Although second generation endocrine therapies have significantly
126 r laparoscopic supracervical hysterectomy or second generation endometrial ablation.
127 ose in the saccharification of cellulose for second-generation ethanol production, and due to this im
128                                We describe a second-generation EWAS approach, which focuses on the po
129 reduced insulin secretion in first- (F1) and second-generation (F2) C57BL/6J male mice offspring.
130 of ferrocene cored polyamidiamine dendrimers second generation (Fc-PAMAM (G2)), after which electrode
131                            The activation of second-generation fluorinated oxazaborolidines by the st
132                  In addition, we transferred second generation (G2) tert blastula cells into WT to pr
133                                            A second-generation ("Gen 2") device capable of surface-in
134                       Phylogenomics based on second-generation genomics and transcriptomics has furth
135           Herein, we report the discovery of second-generation GluN2C/D-selective NMDAR-positive allo
136 ile suppressing desallyl products using both second-generation Grubbs and second-generation Hoveyda-G
137 oup significantly outperformed the benchmark second-generation Grubbs catalyst in the ethenolysis of
138 pooled meta-analyses showed that nonsedating second-generation H(1)-antihistamines (nsAHs) are effect
139 s' first generation (G1) and Hoveyda-Grubbs' second generation (HG2) catalyst under identical conditi
140          Herein we describe the discovery of second-generation HIF-2alpha inhibitor PT2977 with incre
141 e addressed these obstacles by engineering a second-generation, high-affinity AXL decoy receptor with
142                      Custirsen (OGX011) is a second generation highly specific antisense oligonucleot
143                                     Although second-generation HIV integrase strand-transfer inhibito
144 thesis-active Ru intermediates formed by the second-generation Hoveyda and Grubbs catalysts.
145 ucts using both second-generation Grubbs and second-generation Hoveyda-Grubbs catalysts.
146 ation: HR, 0.90; 95% CI, 0.68-1.20; P = .49; second generation: HR, 1.19; 95% CI, 0.82-1.73; P = .36)
147  compared the performance of three available second-generation human genome-wide CRISPR-KO libraries
148                              GSK3532795 is a second-generation human immunodeficiency virus type 1 (H
149 cular outflow [Trabectome, iStent (first and second generations), Hydrus microstent, Kahook Dual Blad
150                                              Second-generation IGRAs had a sensitivity of 94.0% (90.0
151 cy and utility of commercially available and second-generation IGRAs in the diagnostic assessment of
152 89.4) for T-SPOT.TB to 80.0% (75.6-83.8) for second-generation IGRAs.
153 nce country, and their Danish-born children (second-generation immigrants), to evaluate the importanc
154 rt, 578 among first-generation and 106 among second-generation immigrants.
155 uding 1 176 419 first-generation and 184 282 second-generation immigrants.
156                   These compounds are useful second-generation in vitro tools and a promising step to
157            From further computational work a second generation, in silico designed catalyst emerged,
158 d QuantiFERON-TB Gold In-Tube [QFT-GIT]) and second-generation (incorporating novel M tuberculosis an
159  subsequently applied to rationally design a second-generation inhibitor scaffold with a nearly optim
160 bitors and to the identification of refined, second generation inhibitors.
161                          We therefore tested second-generation inhibitors of the 20S proteasome (dela
162 es, which highlights a need for discovery of second-generation inhibitors.
163                                     Although second-generation INSTIs present higher barriers to the
164 ent drug resistance (PDR) on the efficacy of second generation integrase inhibitors.
165 ed the performance of the first (PQ-CSF) and second generation (IQ-CSF) RT-QuIC assays, and investiga
166             We found that treatment with the second-generation irreversible HER-family inhibitors, pa
167    A recent clinical trial of carfilzomib (a second-generation irreversible PI) demonstrated improved
168                             Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inh
169                                  ME-344 is a second-generation isoflavone with unusual cytotoxic prop
170                                            A second generation leishmanization is described here usin
171                                       NLC, a second-generation lipid nanocarrier, upsurges the drug p
172 B and VEGFR2 in the 7-d first generation and second generation lungs.
173  or chloroquine, often in combination with a second-generation macrolide, are being widely used for t
174 identify mutations that confer resistance to second-generation maturation inhibitors and provide nove
175 developed bevirimat analogs, referred to as "second-generation" maturation inhibitors, overcome this
176 ign and engineer artificial pathways towards second generation meroterpenoids with valuable bioactivi
177                                      Here, a second-generation method is described for cryopreservati
178 s of AD, and review recent studies using the second-generation mice.
179  care, who had been identified as a first or second generation migrant from a high-risk country.
180 he unique, non-Western context of Hong Kong, second-generation migrants had higher risk of hospitaliz
181 h provides means for rational development of second-generation MINIs.
182                   Herein we report three new second-generation molecular motors featuring a phosphoru
183  cause additional phenotypes unrelated to AD Second-generation mouse models contain humanized sequenc
184 tution to provide highly efficient DABOs as "second generation" NNRTIs.
185                          Herein, we describe second-generation NS5B inhibitors including GSK8175 (49)
186 nvestigate the safety and performance of the second generation of an implantable intraocular pressure
187  studies reported high diagnostic value of a second generation of cerebrospinal fluid (CSF) Real-Time
188 progenitor cells capable of giving rise to a second generation of odontoblasts during reparative dent
189 nt was the addition of only 3 wt.% Re in the second generation of single crystal Ni-based superalloys
190                             We now present a second generation of UAS- and LexA-responsive CLIPf, SNA
191  modulator, we describe the development of a second generation of utrophin modulators, based on the b
192                In this study, we developed a second generation of vector systems for enhanced transcr
193 rtic valve replacement (TAVR) with first and second generations of transcatheter valves.
194  reprogram somatic cells to pluripotency, a "second generation" of cellular reprogramming involves li
195 way inflammation not only in first- but also second-generation offspring but does not increase suscep
196 to adulthood and transmitted the reporter to second-generation offspring.
197 hagy than all previous datasets, producing a second-generation ontology of 220 functions.
198                                     From the second generation onward, the lineage bred endogamously
199  in optobiology, focusing on new features of second-generation optobiological tools.
200 sed after or were refractory to at least one second-generation or later TKI or were intolerant to sec
201 eneration or later TKI or were intolerant to second-generation or later TKIs and intolerant or refrac
202                     Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor
203                               Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 k
204 e-activity studies led to the discovery of a second-generation ozonide, artefenomel (OZ439, 2), which
205 effects in collagen-induced arthritis of the second generation PAD inhibitor, BB-Cl-amidine.
206 s of oncolytic PVs, including development of second-generation parvoviruses with enhanced oncolytic a
207                         Here, we show that a second-generation PC-positive (PC(+)) DISC (DISCII) vacc
208                                              Second generation peptides were then designed to further
209                               The binding of second-generation peptides to Ral proteins was quantifie
210 iodegradable polymer DES generations against second-generation permanent polymer DES needs to be expl
211 ent and the noninferiority to the thin-strut second-generation permanent polymer drug-eluting stent.
212  the third-generation IMiD pomalidomide, the second-generation PIs carfilzomib and ixazomib, the DACI
213                Platelet-rich fibrin (PRF), a second-generation platelet concentrate, has been the foc
214                              GSK2838232 is a second-generation, potent, small-molecule, oral human im
215    Herein, we show that first generation and second generation progeny from gestationally SS-exposed
216 ic valve implantation in BAV and analyze the second-generation prostheses geometry postimplantation.
217                                              Second-generation prostheses similarly reshape the aorti
218 nical progress has been made with the use of second-generation proteasome inhibitors (PIs).
219 highly effective drugs, including first- and second-generation proteasome inhibitors, immunomodulator
220 SPO), a biomarker of neuroinflammation, most second-generation radioligands are sensitive to the sing
221                                 Profiling of second-generation RAF inhibitors confirmed their improve
222 MR of the inserted species of both first and second generation RCM catalysts are reported and discuss
223                          The first option is second-generation real-time quaking-induced conversion (
224  measurements of prion seeding activity with second-generation real-time quaking-induced conversion (
225            Currently, there exist no data on second-generation recurrence rates among families affect
226  3 months, or an e-cigarette starter pack (a second-generation refillable e-cigarette with one bottle
227 O of the TCRbeta chain in combination with a second-generation retroviral CAR transduction including
228 e bipolar cell-selective photoswitch DAD and second-generation RGC-targeting photoswitch PhENAQ, we i
229 y or assemble full-length mRNA isoforms from second-generation RNA-seq data, it remains a challenge t
230                      Compared with SAVR, the second-generation SAPIEN XT balloon-expandable valve has
231                The SOLVE-TAVI (Comparison of Second-Generation Self-Expandable Versus Balloon-Expanda
232 igh-accuracy, and high-throughput short-read second-generation sequencer to generate over 100 kb of l
233  Generation Sequencing (TGS) long reads with Second Generation Sequencing (SGS) short reads, the accu
234                                              Second generation sequencing technologies are being incr
235 ctively address the read length issue of the second generation sequencing technology, but contain app
236  in order to attain bacterial diversity from second generation sequencing, Hill number can be a good
237 g reads can be corrected by the high-quality second-generation sequencing (SGS) short reads, which is
238 pmental disorders has been revolutionized by second-generation sequencing combined with international
239 ariations rely on short, accurate reads from second-generation sequencing devices.
240                                              Second-generation sequencing technologies have been exte
241 ing reads that are substantially longer than second-generation sequencing technologies.
242 ata from long DNA molecules using economical second-generation sequencing technology.
243                        Massively parallel or second-generation sequencing-based genomic studies conti
244 tellite arrays not accessible to single-cell second-generation sequencing.
245                                            A second-generation series improved on affinity by incorpo
246  rise to the development of a more efficient second-generation set of olefin cross-coupling condition
247 We then expanded the barcoding approach in a second-generation SIVmac239 stock (SIVmac239M2) with ove
248                 Here, we report an improved, second-generation SPARK2 that incorporates a luciferase
249 t inhibition of SRC-3 and SRC-1 with SI-2, a second-generation SRC-3/SRC-1 small-molecule inhibitor,
250 ned from this maturation were used to design second-generation stapled peptides based on RLIP76 that
251                                            A second-generation strategy was then developed to access
252 n effect estimates were found for RCTs where second-generation sulfonylureas were used as a proxy for
253 ive real-world risk of SCA/VA among users of second-generation sulfonylureas: glimepiride, glyburide,
254                       A catalytic asymmetric second generation synthesis of (4S,5S)-4,8-dihydroxy-3,4
255                       A concise and scalable second generation synthesis of HIV maturation inhibitor
256 synthetic strategy, which also resulted in a second-generation synthesis of amphilectolide, confirms
257                   The key innovation in this second-generation synthesis of illudinine is the use of
258                         The application to a second-generation synthesis of the C15-C24 northern port
259                   In addition, we describe a second-generation synthesis of the clinical candidate BM
260 armacophore and assessed binding efficacy of second-generation TDZD analogs (TDZD-10 and Tideglusib)
261 t discovery and modified base detection than second generation technologies.
262                                              Second-generation tests, however, might have sufficientl
263 50-85% of patients with TNBC and developed a second-generation TF-targeting antibody-like immunoconju
264 nd provide a means for rationally developing second-generation therapies.
265 ear) with the potential benefit in favour of second-generation TKI (willingness to pay $200 000 per Q
266 case 0.89, range 0-1) and the annual cost of second-generation TKIs (base case US$152 814 [ie, the pr
267            Considering the current prices of second-generation TKIs and of generic imatinib under dif
268 lower cost of generic imatinib, the value of second-generation TKIs as frontline therapy for this par
269 btained an ICER of $22 765 208, meaning that second-generation TKIs as frontline therapy to achieve s
270 ion of patients achieving such response with second-generation TKIs at 66%, 88%, and a near-perfect r
271 n the USA, Europe, and developing countries, second-generation TKIs at current prices do not offer go
272  showed potential treatment value for use of second-generation TKIs at the current prices in the USA
273 ange 0-240 000) on the cost-effectiveness of second-generation TKIs compared with generic imatinib.
274  was approved for pediatric CML in 2003, the second-generation TKIs dasatinib and nilotinib were rece
275                                Highly priced second-generation TKIs might offer deep molecular respon
276 ditionally, the frontline CML treatment with second-generation TKIs produces deeper molecular respons
277 pay of $50 000 per QALY, the annual price of second-generation TKIs should not exceed $10 000 per yea
278    We aimed to assess the potential value of second-generation TKIs used as frontline therapy in pati
279 ple, considering a scenario in the USA using second-generation TKIs versus imatinib (annual price $44
280 ty of the chronic phase of 0.1), the cost of second-generation TKIs would need to be less than $25 00
281  estimated at 26% with imatinib and 44% with second-generation TKIs.
282                           (18)F-DPA-714 is a second-generation tracer for PET imaging of the 18-kDa t
283 of this study was to compare (18)F-DPA714, a second-generation translocator protein tracer, with (11)
284 tection of certain ions, we have developed a second-generation transmission mode (TM) AP-MALDI imagin
285 ion in daytime ASBP was observed with RSD in second-generation trials (6.12 mm Hg vs. 2.14 mm Hg; p i
286            The intravenous solutions of both second-generation triazoles showed characteristics that
287 herapy, aerosolized delivery with one of the second-generation triazoles was considered.
288 g and can potentially be addressable through second-generation TRK inhibitors(9-11).
289  resonance imaging (MRI) brain scan with the second-generation TSPO ligand [(11)C]PBR28.
290             The present study uses the novel second-generation TSPO PET radioligand [(18)F]FEPPA to e
291                  Human PET imaging using the second-generation TSPO radiotracer [(11)C]DPA-713 reveal
292 mission tomography (MR-PET) scanner with the second-generation TSPO radiotracer [(11)C]PBR28.
293 is study was to directly compare 2 promising second-generation TSPO tracers, (11)C-DPA-713 and (18)F-
294                         It is a high-quality second-generation TSPO-binding PET radiotracer.
295 I] (1) with potassium graphite produces the "second-generation" uranocene [(eta(5) -C(5) (i) Pr(5) )(
296                           Efforts to develop second-generation vaccine candidates may concentrate on
297       Similar patterns were observed for the second-generation vaccine.
298 red that nearly 10% of candidate DNMs in the second generation were post-zygotic, and present in both
299 tion and generational status (i.e., first or second generation) with death among children of immigran
300 n embryo viability was carried over into the second generation without further selection and was equa

 
Page Top